Navigation Links
FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
Date:5/13/2008

DELAND, Fla., May 13 /PRNewswire/ -- USHIFU, LLC, the clinical trial management provider for Focus Surgery, Inc. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 in men who have failed external beam radiation therapy.

Dr. Herbert Lepor, Chairman of Urology at NYU School of Medicine and medical monitor for the trial said, "It is my pleasure to serve as the medical monitor for the prostate cancer clinical trial program evaluating the safety and effectiveness of the Sonablate(R) 500 HIFU device."

"I have personally reviewed the preliminary data and observed the Sonablate(R) 500 in action and I am impressed with this advanced technology for ablating the prostate. These rigorous clinical trials will help define the appropriate role of the Sonablate(R) 500 device in the treatment of prostate cancer," Lepor added.

This trial will be conducted at various sites across the U.S. and is expected to enroll approximately 202 subjects and 10 clinical centers. This clinical trial is based on results from the feasibility trial completed in October 2007 which enrolled 11 subjects from two clinical research sites within the U.S. Ten of the eleven subjects had failed external beam radiation therapy prior to participating in the clinical trial. The results of this feasibility trial provided a basis for the pivotal study. Additional studies are still needed to satisfy the safety and effectiveness standards, including long term outcomes, set by the FDA for marketing approval.

The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate canc
'/>"/>

SOURCE USHIFU, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
4. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
7. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
8. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
9. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
10. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
11. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... BOTHELL, Wash. and VANCOUVER, British ... Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that ... SYNERGY trial showed a benefit with custirsen therapy in ... a poor prognosis. The analysis, exploring the effect of ... showed that over 40 percent of men in the ...
(Date:5/30/2015)... Caris Life Sciences®, a leading biotechnology ... medicine, today announced the presentation of data from ... Molecular Intelligence®, the company,s panomic comprehensive tumor profiling ... histological features. In separate presentations at the annual ... (ASCO) in Chicago, Ill. , ...
(Date:5/29/2015)... May 29, 2015  Today, UL LLC, a ... global provider of electronic quality management systems (EQMS) ... which will leverage the strengths of both organizations ... system implementation and comprehensive advice and guidance for ... EQMS capabilities to UL,s strength in regulatory services ...
Breaking Medicine Technology:OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 2OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 4OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 5OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 6Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6UL and MasterControl collaborate to provide medical manufacturers full service QMS and Regulatory Submissions support 2UL and MasterControl collaborate to provide medical manufacturers full service QMS and Regulatory Submissions support 3
... Jan. 14 Osteotech, Inc. (Nasdaq: OSTE ), a ... today reported preliminary unaudited revenue for the fourth quarter of 2009 ... for the same period in 2008.  During the fourth quarter, the ... its new innovative products all currently in limited launch phases.  Revenue ...
... , BEDFORD, Ohio , ... Ben Venue Laboratories, Inc., is pleased to announce FDA approval ... its existing Fluconazole Injection line. This product is AP rated ... an antifungal agent indicated for oropharyngeal and esophageal candidiasis, cryptococcal ...
Cached Medicine Technology:Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 2Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 3Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 4Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection 2Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection 3Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection 4
(Date:5/30/2015)... ProIntro Magnify contains 30 self-animating and minimalistic Titles including ... elegant opening title to any Final Cut Pro X ... layouts. ProIntro Magnify is created exclusively for Final Cut Pro ... Simply drag a preset into the FCPX timeline ... Inspector window then watch as ProIntro Magnify does the rest. ...
(Date:5/30/2015)... Angeles, CA (PRWEB) May 30, 2015 ... Caregiver Services in coordination with ONEgeneration Senior Enrichment Center, ... Area Manager Raymond de Guzman and Brain Fitness Program ... who joined this event learned that there are many ... Director Tee Bar showed the residents the different ways ...
(Date:5/30/2015)... 30, 2015 The iconic American actor, ... be hosting a new segment on Medical Malpractice. This ... medical malpractice in the health care field. , According ... of medical malpractice suits were filed, roughly only 20% ... settled out of court, while the remaining 30% were ...
(Date:5/30/2015)... New York, NY (PRWEB) May 30, 2015 ... on Wednesday, May 26th 2015, announcing that, “criminals used ... access to information on approximately 100,000 tax accounts through ... information, date of birth and street address.” , ... security industry to have to think it was only ...
(Date:5/29/2015)... CO (PRWEB) May 29, 2015 What ... from The Denver Foundation, community comes together to plant ... to build neighborhoods and awareness of critical issues. Community ... Metro Denver and beyond. , "What Community Does" was ... community foundation in Colorado, and released during the foundation’s ...
Breaking Medicine News(10 mins):Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 2Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 3Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 4Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 5Health News:What Community Does: A New Video from The Denver Foundation 2
... the only treatment for a deteriorated hip joint. Now a ... replacements.// ,Bobby Castor plays on his school’s golf team. ... condition called avascular necrosis. Decreased blood flow caused his hip ... it hurt Castor’s game. “I was just limping around the ...
... People in the United States have steadily increased their ... person // in 1966 to 81 pounds per person ... significant higher levels of arsenic than other poultry or ... farmers use to control intestinal parasites in chickens. ...
... that strongly activates certain systems in the brain.// The ... often addictive. According to the 2000 National Household Survey ... United States have tried methamphetamine at least once in ... users and 18 healthy people to determine how brain ...
... that infects and destroys T-cells in the immune system. ... there are between 800,000 and 900,000 people living with ... less likely to be infected with HIV, and a ... from nine specimens of human foreskin. They found each ...
... people at increased risk for HIV and other infectious ... ,Shyness has been linked to infectious disease for ... noted people with a "melancholic temperament" were more likely ... that theory, showing introverts are more susceptible to upper ...
... SARS case in six months may have the coronavirus ... it was waiting for more results to come in.// ... may have contracted the SARS coronavirus," Xu Ruiheng, deputy ... control, said on Hong Kong cable television, citing results ...
Cached Medicine News:
... comfortable eye protection Properly manufactured radiation ... scatter radiation. Our high quality frames and ... with minimized weight. Our lenses are made ... meet all industry standards. Most Pulse Glasses ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
... lenses and frames are designed with the safety ... lenses are Schott RS-520 (also called SF-6) leaded ... These lenses meet standards, as set for optical ... ,While our eyewear is protecting your eyes, ...
Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co...
Medicine Products: